证券代码：301089 证券简称：拓新药业 公告编号：2025-068 拓新药业集团股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或者重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形。 1.现场会议召开时间：2025年12月18日（星期四）上午9:00 2.网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为2025 年12月18日（星期四）的交易时间，即9:15-9:25，9:30-11:30和13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025年12月18日 9:15-15:00期间的任意时间。 （二）会议召开地点：拓新药业集团股份有限公司会议室。 （三）会议召开方式：采取现场投票与网络投票相结合的方式。 （四）会议召集人：公司董事会 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开时间： （五）会议主持人：经半数以上董事共同推举，由董事杨邵华先生主持本次 会议。 （六）本次股东会的召集、召开及表决方式符合《中华人民共和国公司法》 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:01050867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于拓新药业集团股份有限公司 2025 年第三次临时股东会的法律意见书 康达股会字【2025】第 0522 号 致：拓新药业集团股份有限公司 关于本《法律意见书》，本所及本所律师谨作如下声明： 1、在本《法律意见书》中，本所及本所律师仅就本次会议的召集和召开程序、召 集人和出席人员的资格、表决程序以及表决结果进行核查和见证并发表法律意见，不对 本次会议的议案内容及其所涉及的事实和数据的完整性、真实性和准确性发表意见。 2、本所及本 ...

Group 1 - The core point of the news is that Toxin Pharmaceutical conducted a block trade of 600,000 shares on December 15, with a transaction value of 14.13 million yuan, accounting for 19.27% of the total trading volume for that day [1][2] - The transaction price was 23.55 yuan per share, which represents a discount of 19.87% compared to the market closing price of 29.39 yuan [1][2] Group 2 - The buyer and seller of the shares were both from GF Securities Co., Ltd., indicating a potential strategic move within the same brokerage [2]

| | 本报告期 | 本报告期比上年同期 增减 | 年初至报告期末 | 年初至报告期 年同期增 | | --- | --- | --- | --- | --- | | 营业收入(元) | 89.653.837.13 | -16. 21% | 271.553.589.37 | | | 归属于上市公司股东 的净利润(元) | -11.880.527.36 | -1. 258. 62% | -30. 161. 076. 91 | -1, ( | | 归属于上市公司股东 的扣除非经常性损益 的净利润(元) | -13, 735, 220. 65 | -478. 34% | -35.942.839.18 | | | 经营活动产生的现金 流量净额(元) | | | -22,789,583.38 | | 公司2024年实现营业收入4.22亿元，同比下降49.53%；归属于上市公司股东的净利润-1988.49万元，上年同期为2.43亿元；归属于上市公司股东的扣除 非经常性损益的净利润-2725.54万元，上年同期为2.32亿元；经营活动产生的现金流量净额1.03亿元，同比增长280.91%。 中国经济网北京12月14日讯 拓 ...

Group 1 - The core point of the article is that TuoXin Pharmaceutical has reported that as of December 10, 2025, the number of its shareholders will reach 19,015 [2]

Core Viewpoint - The company,拓新药业, is focused on research, production, and sales in the pharmaceutical and health sector, with a diversified business layout covering APIs, pharmaceutical intermediates, and functional food ingredients [1] Business Operations - The company has established a broad product line that serves key health areas such as antiviral, antitumor, and neurological medications, as well as functional foods [1] - The company’s subsidiary, 新乡制药, is producing and supplying the antiviral drug Ribavirin in a large-scale and stable manner to meet the public health demand during the flu season [1] Market Demand and Supply - Ribavirin is identified as a broad-spectrum and potent antiviral drug, serving as a key component in related antiviral medications [1] - The company has sufficient supply of APIs, which provides critical support for downstream formulation companies in producing flu treatment drugs, thereby alleviating market pressure during peak flu periods [1] Future Prospects - The company is actively pursuing the development of new antiviral drugs targeting influenza, aiming to address future market demands [1]

Core Viewpoint - The company, Tuoxin Pharmaceutical, is committed to research, production, and sales in the pharmaceutical and health sector, with a diversified business layout covering APIs, pharmaceutical intermediates, and functional food ingredients [1] Group 1: Business Operations - The company has established a wide product line that serves key health areas such as antiviral, antitumor, neurological medications, and functional foods [1] - Tuoxin Pharmaceutical's subsidiary, Xinxiang Pharmaceutical, is producing and supplying Ribavirin API in a large-scale and stable manner to meet the public health demand during the current flu outbreak [1] Group 2: Market Demand and Supply - Ribavirin is recognized as a broad-spectrum and potent antiviral drug, serving as a key component in related antiviral medications [1] - The sufficient supply of APIs from the company provides critical support for downstream formulation companies in producing flu treatment drugs, effectively addressing the medication demand during the flu peak [1] Group 3: Future Developments - The company is actively pursuing the development of new antiviral drugs targeting influenza, aiming to meet future market demands [1]

Group 1 - Dongfang Electric announced that three executives plan to reduce their holdings by a total of no more than 30,000 shares due to personal financial needs [1] - Yahu Pharmaceutical's APL-1401 clinical trial data was presented at the 19th European Colorectal Congress, indicating progress in treating moderate to severe ulcerative colitis [1] - Guizhou Bai Ling's actual controller is under investigation by the China Securities Regulatory Commission for insider trading and information disclosure violations [3] Group 2 - Bairen Medical's ePTFE pericardial membrane product has been approved for registration, ending the reliance on imports for this product in the domestic market [4] - Qianxin received approval for a total of 2 billion yuan in technology innovation bonds, with plans to issue medium-term notes and short-term financing bonds [6] - Tengjing Technology's shareholder plans to reduce holdings by no more than 1.96% of the company's shares [7] Group 3 - Yuntianhua's subsidiary is required to pay 386 million yuan in overdue taxes and penalties, which will impact the company's net profit for 2025 [8] - Jianyou Pharmaceutical's propofol emulsion injection has received FDA approval in the United States [9] - Suzhou Gaoxin successfully acquired land use rights for a residential project for 360 million yuan [9] Group 4 - Chalco International's subsidiary won a bid for a 3.03 billion yuan electrolytic aluminum project [11] - Tai Long Pharmaceutical's stock will continue to be suspended due to potential changes in control as the major shareholder is planning a share transfer [12] - Qianli Technology reported a 63.44% year-on-year increase in automobile sales for November, although new energy vehicle sales decreased by 43.98% [13] Group 5 - Fosun Pharma's innovative drug FXS0887 has received approval for a Phase I clinical trial for advanced malignant solid tumors [14] - Guoen Co. has obtained approval for a project to produce 20,000 square meters of aviation-grade acrylic glass, with a total investment of 560 million yuan [15] - Guofa Co.'s chairman resigned due to personal reasons [17] Group 6 - Shanghai Construction won a bid for a state-owned construction land use right for 264 million yuan [18] - Weixin Kang's subsidiary received approval for a clinical trial of lidocaine cream for local anesthesia [20] - Sanxing Medical's subsidiary is a candidate for a 152 million yuan transformer procurement project for the State Grid [20] Group 7 - People's Daily announced the resignation of its president due to work changes, while retaining other leadership roles [21] - Beibu Gulf Port reported a 0.29% year-on-year increase in cargo throughput for November [22] - Chongqing Construction won three engineering projects with a total value of approximately 2.773 billion yuan [23] Group 8 - Xingyu Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [24] - Huajian Group signed a design contract worth 160 million yuan for a comprehensive project [25] - Wankai New Materials plans to invest 350 million yuan in a technical transformation project for producing 100,000 tons of adipic acid [26] Group 9 - Kaipuyun received a government subsidy of 18 million yuan, which is 87.43% of its net profit for the last audited fiscal year [28] - Ningbo Port expects a 10.8% year-on-year increase in container throughput for November [30] - An Cai High-Tech plans to invest 498 million yuan to upgrade its photovoltaic glass production line [32] Group 10 - Shunhao Co. stated that its existing business has not generated synergies with the rail business, which faces various risks [34] - Yihualu plans to publicly transfer 35% of its stake in Liaoyun Company [35] - ST Wanfang's shareholder plans to reduce holdings by no more than 3% of the company's shares [36] Group 11 - Youyou Food's shareholder plans to reduce holdings by no more than 110,000 shares [38] - Hengtong Optic-Electric's incentive fund has spent 49.98 million yuan to purchase company shares [41] - Zoli Pharmaceutical plans to issue convertible bonds to raise no more than 1.556 billion yuan for various projects [42]

Core Viewpoint - The company,拓新药业, reported that as of November 28, 2025, it expects to have 20,014 shareholders [2] Summary by Relevant Categories Company Information - The company has communicated its shareholder count projection for the future, indicating a specific number of 20,014 shareholders by the end of November 2025 [2]

Core Viewpoint - The company,拓新药业, is set to invest in a biomanufacturing base for raw materials and health dietary supplements in Inner Mongolia, with a total investment of 420 million yuan, aimed at enhancing production efficiency and market competitiveness [1] Investment Project Details - The investment agreement will be signed with the People's Government of Tokto County, Inner Mongolia [1] - The total investment for the project is 420 million yuan, with approximately 300 million yuan allocated for fixed asset investment [1] - The project aims to leverage the geographical advantages and resource endowments of Tokto County to establish a large-scale, standardized production base [1] Strategic Benefits - The investment will create favorable conditions for efficient research and production activities [1] - The abundant energy resources in the area are expected to help the company reduce production costs and expand profit margins [1] - Upon completion, the project will enhance the company's industrial chain layout, solidify its market position, and improve core profitability and sustainable development capabilities [1]